



Contact: Hannah Walford
hwalford@sloweymcmanus.com
781-291-0441

Fractyl Health to Host American Diabetes Association 2022 New England Tour de Cure

LEXINGTON, MA – NOVEMBER 1, 2021 – The American Diabetes Association® (ADA) has announced today that Lexington-based [Fractyl Health](#) will be a premier sponsor and host of the [2022 New England Tour de Cure](#).

As the ADA's premier fundraising and engagement event, the Tour de Cure honors those living with diabetes by bringing together thousands of people in a fun and exciting cycling challenge. This will be the first in-person Tour since 2019 and it will consolidate what have historically been several area events into a single regional festivity.

“After many years of participating in this wonderful annual event, Fractyl Health is proud to serve as the host and headquarters for cyclists across New England as they raise funds and awareness about diabetes – and especially, about the need for a cure,” said Margaret Borys, Chief Commercial Officer at Fractyl Health. “While real progress has been made in finding a cure for type 1 diabetes, today we are still treating type 2 diabetes by managing symptoms, with a very large burden on patients to manage this progressive and devastating disease. Our whole purpose at Fractyl Health is to develop new treatments that can address the root cause of type 2 diabetes. For that reason, the Tour is close to our hearts, and we look forward to riding alongside others in the community who are also motivated to find a cure for both types of diabetes.”

“We are thrilled to be partnering with Fractyl Health on next year’s Tour de Cure. We hope to encourage the community to learn the risks and effects of diabetes, promote the benefits of physical activity and support our mission to deliver cutting-edge diabetes research. Through our education and programs, we advocate for the over 34 million Americans living with diabetes,” said Susan Sarro, Executive Director of the ADA’s New England chapter.

The Tour de Cure is also a unique opportunity for Lexington's [Hartwell Innovation Park](#) to bring together businesses, friends, and families as they connect and form teams to support the mission of the ADA. To register or access information for the upcoming 2022 ADA New England Tour de Cure in August, [click here](#).

###

American Diabetes Association

Every day more than 4,000 people are newly diagnosed with diabetes in America. More than 122 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 81 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800- 342-2383). Join the fight with us on Facebook (Tour de Cure: New England Community), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).

About Fractyl Health

Fractyl Health is dedicated to developing novel treatments for metabolic diseases based on innovative scientific insights into the root causes of metabolic dysfunction. Fractyl Health’s lead product candidate, the Revita® DMR System, is designed to be an outpatient endoscopic procedure for the thermal ablation of the duodenal mucosa to improve glycemic control and eliminate insulin needs in T2D patients that are inadequately controlled on long-acting insulin. The company’s discoveries offer the potential to address other metabolic diseases in the future, including nonalcoholic fatty

liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), in an effort to potentially reduce the global economic and healthcare burden of metabolic disease. Fractyl Health is a private life sciences company based in Lexington, Mass. For more information, visit www.fractyl.com or www.twitter.com/FractylHealth

About the Revita® DMR Treatment

Revita® DMR is based on Fractyl Health's breakthrough insights surrounding the role of the gut in metabolic diseases. An outpatient endoscopic procedure, Revita® DMR resurfaces the lining of the upper intestine (duodenal mucosa) to reset the body's metabolism. Data from clinical trials involving close to 300 patients indicate that one-time Revita® DMR treatment is safe and well tolerated, and can produce durable, clinically meaningful improvements in glycemic control and liver fat fraction. In April 2016, the Revita® DMR System received a CE mark in the European Union. In the United States, Revita® is approved for investigational use only by the U.S. Food and Drug Administration. The Revita® DMR System may be available for investigational use in other regions.